ICICI Prudential Arbitrage Fund
Mankind Pharma Limited · NSE
69,750 sh · ₹17.46 Cr
SBI Large Cap Fund
1.8% of their portfolio
₹985.32 Cr
40,72,930 sh
Nippon India Growth Mid Cap Fund
1.9% of their portfolio
₹976.48 Cr
39,00,000 sh
HDFC Large Cap Fund
1.7% of their portfolio
₹662.74 Cr
27,39,492 sh
Nippon India Large Cap Fund
1.0% of their portfolio
₹534.46 Cr
21,34,592 sh
Aditya Birla Sun Life Flexi Cap Fund
1.6% of their portfolio
₹423.80 Cr
16,64,835 sh
Nippon India Pharma Fund
4.4% of their portfolio
₹401.50 Cr
16,03,562 sh
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
5.5% of their portfolio
₹372.19 Cr
15,07,093 sh
ICICI Prudential Healthcare Fund
5.0% of their portfolio
₹346.05 Cr
13,82,093 sh
Aditya Birla Sun Life Large Cap Fund
1.1% of their portfolio
₹321.37 Cr
12,62,461 sh
SBI Contra Fund
68.0% of their portfolio
₹321.28 Cr
13,28,039 sh
Nippon India ELSS Tax Saver Fund
1.6% of their portfolio
₹224.24 Cr
8,95,593 sh
Nippon India Flexi Cap Fund
1.9% of their portfolio
₹172.36 Cr
6,88,395 sh
FIIs trimmed their stake −0.8pp QoQ
Jun 2026 quarter
Ownership by quarter
Promoter
— 0.0pp
ICICI Prudential Arbitrage Fund
Mankind Pharma Limited · NSE
69,750 sh · ₹17.46 Cr
ICICI Prudential Healthcare Fund
Mankind Pharma Limited · NSE
13,82,093 sh · ₹346.05 Cr
ICICI Prudential Nifty Midcap 150 ETF
Mankind Pharma Limited · NSE
20,470 sh · ₹5.13 Cr
Nippon India ELSS Tax Saver Fund
Mankind Pharma Limited · NSE
8,95,593 sh · ₹224.24 Cr
ICICI Prudential Nifty LargeMidcap 250 Index Fund
Mankind Pharma Limited · NSE
4,024 sh · ₹1.01 Cr
Nippon India Growth Mid Cap Fund
Mankind Pharma Limited · NSE
39,00,000 sh · ₹976.48 Cr
ICICI Prudential BSE 500 ETF
Mankind Pharma Limited · NSE
2,051 sh · ₹51.38 L
ICICI Prudential Nifty Pharma Index Fund
Mankind Pharma Limited · NSE
18,737 sh · ₹4.69 Cr
ICICI Prudential Nifty Healthcare ETF
Mankind Pharma Limited · NSE
23,178 sh · ₹5.80 Cr
Scheduled events are part of Pro.
NSE publishes this company's forthcoming board-meeting dates — results, dividends, fund raising — about two weeks ahead.
1 scheduled event on NSE's calendar right now.
The announcements library is part of Pro.
Every exchange filing this company makes — results, board meetings, dividends, analyst meets, investor presentations — as filed with NSE / BSE, the day it lands.
67 announcements on record for this company.
Promoter holding by quarter: Jun 2025 72.7%, Sep 2025 72.7%, Dec 2025 72.7%, Mar 2026 72.7%. Dec 2024, Mar 2025: no filing.
FII
— −1.1pp
FII holding by quarter: Jun 2025 13.1%, Sep 2025 12.8%, Dec 2025 11.3%, Mar 2026 10.2%. Dec 2024, Mar 2025: no filing.
DII
— +1.2pp
DII holding by quarter: Jun 2025 11.5%, Sep 2025 11.9%, Dec 2025 13.3%, Mar 2026 14.5%. Dec 2024, Mar 2025: no filing.
MF
— +1.1pp
MF holding by quarter: Jun 2025 7.3%, Sep 2025 7.8%, Dec 2025 9.3%, Mar 2026 10.4%. Dec 2024, Mar 2025: no filing.
Per-series scale, bounds labeled. Gaps mark quarters without a filing.
Nippon India Retirement Fund - Wealth Creation Scheme
Mankind Pharma Limited · NSE
76,526 sh · ₹19.16 Cr
Ownership by quarter
Promoter
— 0.0pp
Promoter holding by quarter: Jun 2025 72.7%, Sep 2025 72.7%, Dec 2025 72.7%, Mar 2026 72.7%. Dec 2024, Mar 2025: no filing.
FII
— −1.1pp
FII holding by quarter: Jun 2025 13.1%, Sep 2025 12.8%, Dec 2025 11.3%, Mar 2026 10.2%. Dec 2024, Mar 2025: no filing.
DII
— +1.2pp
DII holding by quarter: Jun 2025 11.5%, Sep 2025 11.9%, Dec 2025 13.3%, Mar 2026 14.5%. Dec 2024, Mar 2025: no filing.
MF
— +1.1pp
MF holding by quarter: Jun 2025 7.3%, Sep 2025 7.8%, Dec 2025 9.3%, Mar 2026 10.4%. Dec 2024, Mar 2025: no filing.
Per-series scale, bounds labeled. Gaps mark quarters without a filing.
Scheduled events are part of Pro.
NSE publishes this company's forthcoming board-meeting dates — results, dividends, fund raising — about two weeks ahead.
1 scheduled event on NSE's calendar right now.
The announcements library is part of Pro.
Every exchange filing this company makes — results, board meetings, dividends, analyst meets, investor presentations — as filed with NSE / BSE, the day it lands.
67 announcements on record for this company.